High TINCR expression indicated markedly poorer prognosis than low TINCR expression did in BRCA patients (Fig. 2b–g) and BLCA, kidney renal papillary-cell carcinoma (KIRP), ovarian serous cystadenocarcinoma (OV), uterine corpus endometrial carcinoma (UCEC), esophageal carcinoma (ESCA), THCA, kidney renal clear-cell carcinoma (KIRC), and stomach adenocarcinoma (STAD) patients (Fig. 2h–s). This evidence concerns the gene TINCR and ovarian serous cystadenocarcinoma.